Skip to content
MarketScale
‹ Back to IndustriesSciences

Beyond Fukushima: Nuclear Energy is Critical to Achieve Net Zero

The Fukushima nuclear plant's planned release of treated radioactive water into the Pacific has renewed international debate over nuclear energy's risks and benefits. Despite ongoing concerns, nuclear power remains a critical component of global strategies to achieve net-zero carbon emissions. Nations must weigh the perceived dangers of nuclear against its proven capacity to provide low-carbon baseload electricity at scale.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Christopher Gadomski · FukushimaFukushima Wastewater ReleaseNuclear EnergyNuclear Power
Share

Key takeaways

01

Japan's release of treated radioactive water from Fukushima has drawn international criticism, including trade restrictions from China.

02

Nuclear energy is increasingly recognized as essential to achieving net-zero emissions targets globally.

03

Policymakers must balance public risk perception of nuclear with its demonstrated value as a reliable, low-carbon energy source.

The Fukushima Nuclear plant fallout continues as nations try to balance the risks while realizing the potential and need for nuclear energy.

Japan initiated its planned release of treated radioactive water from the Fukushima nuclear plant into the Pacific, a decision that has drawn international criticism and economic consequences. In a swift response, China immediately banned all Japanese aquatic products, voicing concerns over potential radioactive contamination. This move, greenlit by the Japanese government two years prior and recently endorsed by the U.N. nuclear watchdog, is a pivotal step in decommissioning the Fukushima Daiichi plant, which suffered severe damage from a 2011 tsunami. However, with protests erupting globally and significant economic implications on the horizon, the long-term effects of this decision remain uncertain.

No matter the decision, many will wonder about its safety/efficacy by Japanese energy officials. How might this decision impact public perception around nuclear energy, especially as citizens gain a renewed interest in its place among renewable energy alternatives?

Christopher Gadomski, Lead Analyst, Nuclear for BloombergNEF, weighed in on the controversial move and its potential impact on seeking nuclear power solutions in the future.

Christopher’s Thoughts

“The level of radiation of tritium in the water is well below world standards. And so, to me, I believe that it’s something that was the right thing to do. I’m head of nuclear research for Bloomberg NEF. I teach economics and finance for New York University, the Center for Global Affairs. I visited Fukushima in 2013 or 2015, two to four years after the accident. And when I was there, you could see already hundreds of these large storage tanks that were accumulating water that had been contaminated.”

Radiation Levels and Safety Measures

“The Fukushima power plant is built on a plateau. They excavated down, and water falls from the mountains behind there through the plateau and came into the basement of the nuclear power plant, came in contact with the melted reactors, and became contaminated. And so to prevent it from running further into the sea, the engineers at Fukushima collected this water.

They put it in storage tanks, and they were contaminated by strontium, cesium, iodine, and various radionuclides. And they have to sort of deal with them. So they applied this advanced liquid processing system that came from, I believe, the Europeans or so.

And this processing took the water and removed all of the 65 radionuclides from the water. What they did not remove from the water was tritium. And they can’t remove tritium because tritium is an isotope of hydrogen.

And it’s very, very difficult to use the Alps system to remove the tritium. So you have, I understand, a thousand tanks on the site now, accumulating something like 100,000 liters of water a day. And you came to the point where you needed to do something. And so, they decided to release the water into the ocean.”

Public Perception and International Reactions

“From what the IAE, the International Atomic Energy Agency, has said, is that the level of radiation of tritium in the water is well below world standards. And so, to me, I believe that it’s something that was the right thing to do because the Japanese have spent the last ten years worrying about trying to collect and treat this water. A variety of international organizations have looked at it and said, yes, it’s below certain levels. And if we do it properly, we can release it out to the sea. It’s what the stars are doing today. When I was in Fukushima again, in 2013 or 2015, we went to a local sushi restaurant and had some fantastic sushi for dinner. And I’m still alive. I have yet to turn green. And so, you know, there is a concern because radiation is one of those things that people don’t quite understand.

We believe the World Health Organization, and we believe the International Atomic Energy Agency, the Japanese government, and TEPCO, the utility, the operating plant, that these may have reduced the danger of this water that’s being released to well below global standards. It’s like eating a couple of bananas a day because there’s a lot of potassium in bananas, which are radioactive. And so if you eat 15 bananas, that’s equivalent to some of the exposure that you would be getting if you were to be in contact with this water.

And, you know, people eat bananas every day. I had mine today. But what I think is happening is that there’s no real love lost between the Chinese, the Japanese, and Koreans on certain levels.

At certain levels, they are cooperating helping each other. On other levels, they’re competing. And so, in my estimation, the efforts by the Koreans and the Chinese, more specifically the Chinese, they’re like sticking their fingers in the Japanese eye by making a very big issue of all of this when theoretically it shouldn’t be an issue.

It’s a concern. You are releasing tritiated water. Tritium has a very short half-life.

It’s an isotope of hydrogen. It is radioactive. But to me, the problem is being blown out of proportion.”

Nuclear Energy’s Role in Achieving Net Zero

“However, it’s something that has to be calculated for all the nuclear industries. It’s another topic that we’re having a tremendous amount of coverage about this event today. And it is another negative label for the nuclear energy industry, which I think is unwarranted. It’s my opinion that if you are really trying to achieve net zero, which many countries worldwide are trying to do, nuclear has to play a key role in doing that as a complement to renewables. And this doesn’t help the public image of nuclear power because they may be releasing this water for many years to come. Everybody loves to hate nuclear power because they’re afraid of it. They don’t understand it.

I drove within 10 yards of the Fukushima reactor that was damaged. I got a slight radiation dose. I’m still here. And I think people don’t understand it. I also traveled to visit that site with some MIT scientists, and they judged the Japanese reaction to the evacuation of all the people from Fukushima as being much greater than warranted. And if you go to Chernobyl these days, I have not been there, but I understand the area is thriving with wildlife. And, you know, low radiation levels persist there, but it has not been ultimately very damaging to people. But it’s a very testy subject. And many people go back and forth and like to explain that there is a real serious problem with radiation.”

International Cooperation in Nuclear Energy

“And going back to the aspect of cooperation, there’s cooperation between General Electric and Hitachi, two leading U.S. and Japanese firms, to commercialize the next generation of nuclear. There is a lot of international cooperation. The Koreas are involved in working with other European companies and building reactors very successfully in the Middle East and working with Westinghouse at times. There are loggerheads regarding licensing the intellectual property of the reactors. But it’s very, very important. It’s a global problem, climate change, the net zero. And aspirations, I think, can only really be addressed if you have a large contribution of nuclear to complement an even larger deployment of renewables.

Yeah, I think that one of the things that I talk about and maintain is that nuclear energy is a very, very critical thing. And those companies, those countries that manage the build-out of their nuclear energy infrastructure, will play a more important role in the future than those countries that ignore it. And I’m concerned right now that the U.

S. , although it’s trying to develop many different types of advanced reactors, other countries, the Russians, and the Chinese, are more aggressive in building and reaching out and building nuclear reactors in other parts of the world. And so the U.

S. , on the surface, seems to be quite well behind the competition in Russia and China for building new reactors around the world. A cooperative agreement between the U.

S. and Japan and U. S.

and Korea to build reactors in this country and elsewhere, I think, would go a long way towards achieving the sustainability goals that we all aspire to.”

Article by James Kent

About the author

Christopher Gadomski
Christopher GadomskiLead Analyst, Nuclear

As a business development and marketing consultant, Mr. Gadomski has advised a wide range of clients from the Government of Egypt to IBM on strategic planning, business development, corporate communications and policy inititiatives. Mr. Gadomski is a faculty member of The Center for Global Affairs at New York University where he teaches courses on Energy Policy, Energy and the Environment, and the Economics and Finance of Energy. He has received the Mitsui Practitioner in Academia grant from The Weissman Center for International Business at the Zicklin School of Business at Baruch College, CUNY in support of syllabus development for Internet Marketing and Global Business courses he has taught there.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Sciences expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

Christopher Gadomski
Christopher Gadomski

Research Director, Nuclear Energy at BloombergNEF (formerly)

Christopher Gadomski is a research analyst and thought leader specializing in nuclear energy and power markets. He has contributed analysis on nuclear energy policy, economics, and the role of nuclear in decarbonization strategies. His work has appeared in industry publications and he has been associated with energy research at major advisory firms including EY.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512